This is a Phase I Study evaluating the safety and feasibility of IL-8 receptor-modified patient-derived activated CD70 CAR T cells in adult patients with brain metastases from primary cancer, with either newly diagnosed lesions or recurrent or progressive disease after prior therapy.
Histological confirmation of primary cancers
Histologic confirmation of CD70 on primary tumor, lymph node, or BM biopsy
At least one recurrent or progressive metastatic lesion or new metastatic lesion(s).
KPS ≥ 70.
Participant has ongoing toxicity ≥ grade 2 per the CTCAE version 5.0 considered clinically significant and in the opinion of the investigator, attributable to prior antineoplastic therapies.
Participant has received any chemotherapy or other immunotherapy within 14 days prior to the first dose of study intervention.
Unstable angina and/or congestive heart failure requiring hospitalization.
Transmural myocardial infarction within the last 6 months.